Acute Respiratory Distress Syndrome – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of acute respiratory distress syndrome (ARDS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of ARDS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s ARDS forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ARDS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following four ARDS patient populations:
- Diagnosed events.
- Diagnosed events by severity.
- Diagnosed events by type of pulmonary injury.
- Diagnosed events of sepsis-related versus non-sepsis-related ARDS.
Note: Coverage may vary by country.
Table of contents
- Acute Respiratory Distress Syndrome - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of acute respiratory distress syndrome)
- Diagnosed events of acute respiratory distress syndrome
- Diagnosed events by severity
- Diagnosed events by type of pulmonary injury
- Diagnosed events of acute respiratory distress syndrome: sepsis-related vs. non-sepsis-related
- Risk / protective factors applied to disease forecast models
- Reference materials
Jackie Liu, M.P.H., Ph.D., Manager, Epidemiology. She first joined Clarivate as a Medtech analyst and worked on forecasting the global vascular devices market. She received her Ph.D. in molecular genetics and her M.P.H. in epidemiology from the University of Toronto in Canada.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.